EXAS - Exact Sciences Corporation Stock Price, News & Analysis

$59.17 -0.58 (-0.97 %)
(As of 11/24/2017 02:39 AM ET)
Previous Close$59.74
Today's Range$58.60 - $59.85
52-Week Range$13.05 - $63.60
Volume745,400 shs
Average Volume2.51 million shs
Market Capitalization$7.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.67

About Exact Sciences Corporation (NASDAQ:EXAS)

Exact Sciences Corporation logoExact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXAS
CUSIP30063P10

Debt

Debt-to-Equity Ratio0.01%
Current Ratio10.34%
Quick Ratio9.98%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$99.38 million
Price / Sales71.29
Cash FlowN/A
Price / CashN/A
Book Value$4.40 per share
Price / Book13.45

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.16)
Net Income$-167,210,000.00
Net Margins-60.71%
Return on Equity-30.32%
Return on Assets-27.37%

Miscellaneous

Employees736
Outstanding Shares119,730,000

Frequently Asked Questions for Exact Sciences Corporation (NASDAQ:EXAS)

What is Exact Sciences Corporation's stock symbol?

Exact Sciences Corporation trades on the NASDAQ under the ticker symbol "EXAS."

How were Exact Sciences Corporation's earnings last quarter?

Exact Sciences Corporation (NASDAQ:EXAS) released its earnings results on Monday, October, 30th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.07. The medical research company had revenue of $72.60 million for the quarter, compared to analysts' expectations of $65.03 million. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm's quarterly revenue was up 158.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.36) EPS. View Exact Sciences Corporation's Earnings History.

When will Exact Sciences Corporation make its next earnings announcement?

Exact Sciences Corporation is scheduled to release their next quarterly earnings announcement on Monday, February, 19th 2018. View Earnings Estimates for Exact Sciences Corporation.

Where is Exact Sciences Corporation's stock going? Where will Exact Sciences Corporation's stock price be in 2017?

13 Wall Street analysts have issued 1 year target prices for Exact Sciences Corporation's stock. Their predictions range from $28.00 to $67.00. On average, they expect Exact Sciences Corporation's stock price to reach $50.77 in the next year. View Analyst Ratings for Exact Sciences Corporation.

What are Wall Street analysts saying about Exact Sciences Corporation stock?

Here are some recent quotes from research analysts about Exact Sciences Corporation stock:

  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (11/2/2017)
  • 2. Cowen Inc analysts commented, "Colon cancer is the #2 cause of cancer death in the US, yet compliance with screening guidelines is low. Exact Sciences' Cologuard is less invasive than colonoscopy, more accurate than alternatives, FDA approved, in guidelines, and increasingly reimbursed. EXAS is targeting $4B of a ~$15B annual market opportunity. The 5-year revenue CAGR is forecast at ~50%. Initiate at Outperform with a $30 PT." (3/27/2017)

Are investors shorting Exact Sciences Corporation?

Exact Sciences Corporation saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 8,794,649 shares, a decrease of 17.9% from the October 13th total of 10,716,019 shares. Based on an average daily volume of 1,980,367 shares, the short-interest ratio is currently 4.4 days. Approximately 7.5% of the shares of the stock are short sold.

Who are some of Exact Sciences Corporation's key competitors?

Who are Exact Sciences Corporation's key executives?

Exact Sciences Corporation's management team includes the folowing people:

  • Kevin T. Conroy, Chairman of the Board, President, Chief Executive Officer (Age 51)
  • Jeffrey Thomas Elliott, Chief Financial Officer (Age 39)
  • Maneesh K. Arora, Chief Operating Officer, Senior Vice President, Director (Age 48)
  • Graham Peter Lidgard Ph.D., Senior Vice President, Chief Scientific Officer (Age 68)
  • D. Scott Coward, Senior Vice President, General Counsel, Secretary (Age 52)
  • David A. Thompson, Lead Independent Director (Age 75)
  • Thomas D. Carey, Independent Director (Age 55)
  • James E. Doyle, Independent Director (Age 71)
  • John A. Fallon M.D., Independent Director (Age 69)
  • Daniel J. Levangie, Independent Director (Age 66)

Who owns Exact Sciences Corporation stock?

Exact Sciences Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include JPMorgan Chase & Co. (2.40%), Gilder Gagnon Howe & Co. LLC (2.12%), Zevenbergen Capital Investments LLC (1.77%), Eagle Asset Management Inc. (1.53%), Wasatch Advisors Inc. (1.30%) and Canada Pension Plan Investment Board (0.78%). Company insiders that own Exact Sciences Corporation stock include D Scott Coward, David Thompson, Graham Peter Lidgard, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling, Maneesh Arora and Thomas D Carey. View Institutional Ownership Trends for Exact Sciences Corporation.

Who sold Exact Sciences Corporation stock? Who is selling Exact Sciences Corporation stock?

Exact Sciences Corporation's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Gilder Gagnon Howe & Co. LLC, Elk Creek Partners LLC, Wasatch Advisors Inc., Neuberger Berman Group LLC, Victory Capital Management Inc., Zevenbergen Capital Investments LLC and Skylands Capital LLC. Company insiders that have sold Exact Sciences Corporation company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Kevin T Conroy and Maneesh Arora. View Insider Buying and Selling for Exact Sciences Corporation.

Who bought Exact Sciences Corporation stock? Who is buying Exact Sciences Corporation stock?

Exact Sciences Corporation's stock was bought by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Canada Pension Plan Investment Board, Hodges Capital Management Inc., Baillie Gifford & Co., Schwab Charles Investment Management Inc., Russell Investments Group Ltd., Sectoral Asset Management Inc and Axiom International Investors LLC DE. Company insiders that have bought Exact Sciences Corporation stock in the last two years include David Thompson, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling and Thomas D Carey. View Insider Buying and Selling for Exact Sciences Corporation.

How do I buy Exact Sciences Corporation stock?

Shares of Exact Sciences Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exact Sciences Corporation's stock price today?

One share of Exact Sciences Corporation stock can currently be purchased for approximately $59.17.

How big of a company is Exact Sciences Corporation?

Exact Sciences Corporation has a market capitalization of $7.15 billion and generates $99.38 million in revenue each year. The medical research company earns $-167,210,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Exact Sciences Corporation employs 736 workers across the globe.

How can I contact Exact Sciences Corporation?

Exact Sciences Corporation's mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.


MarketBeat Community Rating for Exact Sciences Corporation (EXAS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  529 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  828
MarketBeat's community ratings are surveys of what our community members think about Exact Sciences Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Exact Sciences Corporation (NASDAQ:EXAS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.62)
Consensus Price Target: $50.77 (14.20% downside)

Consensus Price Target History for Exact Sciences Corporation (NASDAQ:EXAS)

Price Target History for Exact Sciences Corporation (NASDAQ:EXAS)

Analysts' Ratings History for Exact Sciences Corporation (NASDAQ:EXAS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017Leerink SwannReiterated RatingOutperform$63.00 -> $67.00N/AView Rating Details
11/13/2017Robert W. BairdDowngradeOutperform -> Neutral$56.00N/AView Rating Details
11/1/2017BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
10/31/2017Bank of America CorporationBoost Price TargetBuy$56.00 -> $58.00N/AView Rating Details
10/31/2017Canaccord GenuityUpgradeBuy$60.00N/AView Rating Details
10/31/2017Craig HallumBoost Price TargetBuy$46.00 -> $61.00N/AView Rating Details
10/31/2017Benchmark Co.Reiterated RatingBuy -> Buy$50.00 -> $60.00N/AView Rating Details
10/31/2017Jefferies Group LLCBoost Price TargetBuy$60.00N/AView Rating Details
7/26/2017Roth CapitalBoost Price TargetBuy$40.00 -> $46.00HighView Rating Details
7/26/2017Lake Street CapitalBoost Price TargetHold -> Hold$30.00 -> $41.00MediumView Rating Details
6/7/2017StephensSet Price TargetHold$28.00MediumView Rating Details
5/31/2017Cowen IncReiterated RatingOutperform$45.00HighView Rating Details
5/1/2017Goldman Sachs Group IncSet Price TargetNeutral$21.00 -> $33.00MediumView Rating Details
7/27/2016MizuhoBoost Price TargetNeutral$10.00 -> $15.00N/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$29.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for Exact Sciences Corporation (NASDAQ:EXAS)

Earnings by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Earnings History by Quarter for Exact Sciences Corporation (NASDAQ EXAS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/19/2018($0.29)N/AView Earnings Details
10/30/2017Q3 2017($0.30)($0.23)$65.03 million$72.60 millionViewN/AView Earnings Details
7/25/2017Q2 2017($0.37)($0.27)$47.73 million$57.65 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.32)$37.38 million$48.36 millionViewN/AView Earnings Details
2/21/2017Q416($0.39)($0.34)$32.53 million$35.24 millionViewListenView Earnings Details
10/26/2016Q316($0.43)($0.36)$25.24 million$28.10 millionViewListenView Earnings Details
7/26/2016Q216($0.55)($0.46)$18.54 million$21.20 millionViewListenView Earnings Details
5/3/2016Q116($0.52)($0.49)$15.17 million$14.80 millionViewN/AView Earnings Details
2/24/2016Q415($0.47)($0.41)$14.96 million$14.40 millionViewListenView Earnings Details
10/29/2015Q315($0.44)($0.45)$12.56 million$12.60 millionViewListenView Earnings Details
7/20/2015Q215($0.45)($0.44)$7.96 million$8.10 millionViewListenView Earnings Details
5/4/2015Q115($0.41)($0.40)$4.11 million$4.30 millionViewN/AView Earnings Details
2/24/2015Q414($0.39)($0.38)$19.90 million$1.15 millionViewN/AView Earnings Details
10/27/2014Q314($0.34)($0.39)$0.13 millionViewListenView Earnings Details
7/22/2014Q214($0.25)($0.24)$0.03 millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.23)$0.40 million$0.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.19)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
10/29/2013Q313($0.18)($0.16)$1.02 million$1.00 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.18)($0.19)$1.02 million$1.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013($0.20)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.18)($0.22)$1.04 million$1.00 millionViewN/AView Earnings Details
10/30/2012Q312($0.21)($0.21)$1.03 million$1.04 millionViewN/AView Earnings Details
7/25/2012($0.20)($0.26)ViewN/AView Earnings Details
5/1/2012($0.18)($0.19)ViewN/AView Earnings Details
2/23/2012($0.17)($0.18)ViewN/AView Earnings Details
11/3/2011($0.15)($0.15)ViewN/AView Earnings Details
8/2/2011($0.10)($0.13)ViewN/AView Earnings Details
5/3/2011($0.09)($0.08)ViewN/AView Earnings Details
2/15/2011($0.08)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exact Sciences Corporation (NASDAQ:EXAS)
2017 EPS Consensus Estimate: ($1.45)
2018 EPS Consensus Estimate: ($0.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.44)($0.40)($0.42)
Q2 20174($0.41)($0.33)($0.38)
Q3 20175($0.35)($0.28)($0.33)
Q4 20176($0.36)($0.29)($0.32)
Q1 20184($0.33)($0.24)($0.27)
Q2 20184($0.33)($0.18)($0.24)
Q3 20184($0.32)($0.10)($0.20)
Q4 20184($0.31)($0.03)($0.15)
Q1 20191($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exact Sciences Corporation (NASDAQ:EXAS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Exact Sciences Corporation (NASDAQ EXAS)

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 86.04%
Insider Trades by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)
Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Insider Trades by Quarter for Exact Sciences Corporation (NASDAQ EXAS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/21/2017Kevin T ConroyInsiderSell134,057$59.50$7,976,391.50View SEC Filing  
11/9/2017Kevin T ConroyCEOSell137,805$59.14$8,149,787.70View SEC Filing  
11/1/2017Graham Peter LidgardInsiderSell45,775$53.60$2,453,540.00View SEC Filing  
10/2/2017D Scott CowardSVPSell29,115$47.16$1,373,063.40View SEC Filing  
10/2/2017Graham Peter LidgardInsiderSell81,025$47.16$3,821,139.00View SEC Filing  
9/5/2017Graham Peter LidgardInsiderSell75,683$40.81$3,088,623.23View SEC Filing  
9/1/2017Graham Peter LidgardInsiderSell45,775$41.49$1,899,204.75View SEC Filing  
8/17/2017Thomas D CareyDirectorBuy2,500$37.71$94,275.00View SEC Filing  
7/31/2017Jeffrey Thomas ElliottCFOSell5,846$39.41$230,390.86View SEC Filing  
7/3/2017D Scott CowardSVPSell1,987$35.21$69,962.27View SEC Filing  
4/3/2017D Scott CowardSVPSell1,543$23.74$36,630.82View SEC Filing  
3/13/2017D Scott CowardSVPSell1,983$21.16$41,960.28View SEC Filing  
3/13/2017Kevin T ConroyInsiderSell12,059$21.16$255,168.44View SEC Filing  
3/13/2017Maneesh AroraCOOSell5,574$21.16$117,945.84View SEC Filing  
2/27/2017D Scott CowardSVPSell7,046$21.48$151,348.08View SEC Filing  
2/27/2017Graham Peter LidgardInsiderSell8,668$21.51$186,448.68View SEC Filing  
2/27/2017Maneesh AroraCOOSell11,114$21.50$238,951.00View SEC Filing  
1/3/2017D Scott CowardSVPSell1,535$13.61$20,891.35View SEC Filing  
12/14/2016David ThompsonDirectorBuy10,000$13.84$138,400.00View SEC Filing  
11/15/2016Kevin T ConroyInsiderSell600,000$17.46$10,476,000.00View SEC Filing  
11/15/2016Maneesh AroraCOOSell562,932$17.46$9,828,792.72View SEC Filing  
9/1/2016Lionel SterlingDirectorBuy5,000$18.10$90,500.00View SEC Filing  
8/3/2016Katherine S ZanottiDirectorBuy3,380$17.93$60,603.40View SEC Filing  
7/26/2016Graham Peter LidgardInsiderSell7,383$14.82$109,416.06View SEC Filing  
7/26/2016Maneesh AroraCOOSell7,359$14.82$109,060.38View SEC Filing  
4/1/2016D Scott CowardSVPSell1,685$6.62$11,154.70View SEC Filing  
3/10/2016D Scott CowardSVPSell2,175$6.05$13,158.75View SEC Filing  
3/10/2016Graham Peter LidgardInsiderSell3,041$6.05$18,398.05View SEC Filing  
3/10/2016Maneesh AroraCOOSell4,042$6.05$24,454.10View SEC Filing  
3/8/2016James Edward DoyleDirectorBuy5,000$6.43$32,150.00View SEC Filing  
3/3/2016Katherine S NapierDirectorBuy3,775$5.38$20,309.50View SEC Filing  
3/1/2016Kevin T ConroyCEOBuy50,000$5.00$250,000.00View SEC Filing  
2/26/2016Kevin T ConroyCEOSell6,895$5.81$40,059.95View SEC Filing  
2/25/2016Graham Peter LidgardInsiderSell2,997$5.52$16,543.44View SEC Filing  
2/25/2016Maneesh AroraCOOSell4,099$5.52$22,626.48View SEC Filing  
2/23/2016Graham Peter LidgardInsiderSell2,411$6.39$15,406.29View SEC Filing  
2/23/2016Kevin T ConroyCEOSell6,866$6.39$43,873.74View SEC Filing  
2/23/2016Maneesh AroraCOOSell2,556$6.39$16,332.84View SEC Filing  
1/11/2016David ThompsonDirectorBuy15,000$6.99$104,850.00View SEC Filing  
2/26/2015Graham Peter LidgardDirectorSell3,938$23.44$92,306.72View SEC Filing  
2/26/2015Kevin T ConroyCEOSell8,425$23.44$197,482.00View SEC Filing  
2/26/2015Maneesh AroraCOOSell3,895$23.44$91,298.80View SEC Filing  
2/24/2015Graham Peter LidgardDirectorSell4,037$22.90$92,447.30View SEC Filing  
2/24/2015Kevin T ConroyCEOSell9,798$22.90$224,374.20View SEC Filing  
2/24/2015Maneesh AroraCOOSell2,995$22.90$68,585.50View SEC Filing  
1/2/2015Graham Peter LidgardInsiderSell3,363$26.72$89,859.36View SEC Filing  
1/2/2015Kevin T ConroyCEOSell9,484$26.72$253,412.48View SEC Filing  
1/2/2015Maneesh AroraCOOSell2,495$26.72$66,666.40View SEC Filing  
10/29/2014Graham Peter LidgardInsiderSell8,015$24.68$197,810.20View SEC Filing  
7/25/2014Graham Peter LidgardVPSell11,081$15.99$177,185.19View SEC Filing  
7/25/2014Kevin T ConroyCEOSell11,336$15.99$181,262.64View SEC Filing  
7/25/2014Maneesh AroraCOOSell9,291$15.99$148,563.09View SEC Filing  
5/5/2014William MeganSVPBuy10,000$11.79$117,900.00View SEC Filing  
2/24/2014Graham Peter LidgardVPSell3,160$14.07$44,461.20View SEC Filing  
2/24/2014Kevin ConroyCEOSell8,708$14.07$122,521.56View SEC Filing  
2/24/2014Maneesh AroraCOOSell2,662$14.07$37,454.34View SEC Filing  
1/2/2014Graham Peter LidgardVPSell10,288$11.96$123,044.48View SEC Filing  
1/2/2014Kevin ConroyCEOSell26,379$11.96$315,492.84View SEC Filing  
1/2/2014Maneesh AroraCOOSell8,627$11.96$103,178.92View SEC Filing  
10/28/2013Graham Peter LidgardVPSell7,430$11.07$82,250.10View SEC Filing  
9/20/2013Sally CrawfordDirectorSell25,000$12.19$304,750.00View SEC Filing  
11/2/2012Kevin T ConroyCEOBuy2,000$9.13$18,260.00View SEC Filing  
11/2/2012Maneesh AroraCFOBuy1,000$9.04$9,040.00View SEC Filing  
11/1/2012Lionel SterlingDirectorBuy5,500$9.08$49,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Exact Sciences Corporation (NASDAQ EXAS)

Source:
DateHeadline
Exact Sciences Corporation (EXAS) Insider Kevin T. Conroy Sells 134,057 SharesExact Sciences Corporation (EXAS) Insider Kevin T. Conroy Sells 134,057 Shares
www.americanbankingnews.com - November 22 at 7:28 PM
Exact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $8 million of SharesExact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $8 million of Shares
finance.yahoo.com - November 22 at 7:12 PM
Exact Sciences, We Bid You FarewellExact Sciences, We Bid You Farewell
seekingalpha.com - November 21 at 6:41 PM
Exact Sciences Corporation (EXAS) Receives Average Recommendation of "Buy" from AnalystsExact Sciences Corporation (EXAS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 20 at 3:48 PM
Roka Bioscience (ROKA) versus Exact Sciences Corporation (EXAS) Financial ContrastRoka Bioscience (ROKA) versus Exact Sciences Corporation (EXAS) Financial Contrast
www.americanbankingnews.com - November 19 at 3:28 PM
EXACT Sciences (EXAS) Presents At Jefferies 2017 London Healthcare Conference - SlideshowEXACT Sciences (EXAS) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 5:18 PM
ETFs with exposure to EXACT Sciences Corp. : November 17, 2017ETFs with exposure to EXACT Sciences Corp. : November 17, 2017
finance.yahoo.com - November 17 at 12:14 PM
Exact Sciences breaks ground on lab, office expansions in MadisonExact Sciences breaks ground on lab, office expansions in Madison
finance.yahoo.com - November 16 at 2:07 PM
$76.55 Million in Sales Expected for Exact Sciences Corporation (EXAS) This Quarter$76.55 Million in Sales Expected for Exact Sciences Corporation (EXAS) This Quarter
www.americanbankingnews.com - November 16 at 11:02 AM
Even Exact Sciences Bulls Wonder If Expectations Are LoftyEven Exact Sciences Bulls Wonder If Expectations Are Lofty
finance.yahoo.com - November 13 at 7:00 PM
Exact Sciences Corporation (EXAS) CEO Sells $8,149,787.70 in StockExact Sciences Corporation (EXAS) CEO Sells $8,149,787.70 in Stock
www.americanbankingnews.com - November 13 at 4:20 PM
Is Exact Sciences Corporation Stock a Buy?Is Exact Sciences Corporation Stock a Buy?
www.fool.com - November 13 at 9:25 AM
Short Interest in Exact Sciences Corporation (EXAS) Declines By 17.9%Short Interest in Exact Sciences Corporation (EXAS) Declines By 17.9%
www.americanbankingnews.com - November 12 at 4:30 AM
Todays Research Reports on Trending Tickers: Exact Sciences and Gilead SciencesToday's Research Reports on Trending Tickers: Exact Sciences and Gilead Sciences
finance.yahoo.com - November 9 at 2:38 AM
Exact Sciences to Expand Laboratory and Corporate Facilities in MadisonExact Sciences to Expand Laboratory and Corporate Facilities in Madison
finance.yahoo.com - November 9 at 2:38 AM
Head to Head Review: Crispr Theraptc (CRSP) and Exact Sciences Corporation (EXAS)Head to Head Review: Crispr Theraptc (CRSP) and Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - November 7 at 11:44 AM
ETFs with exposure to EXACT Sciences Corp. : November 6, 2017ETFs with exposure to EXACT Sciences Corp. : November 6, 2017
finance.yahoo.com - November 6 at 8:15 PM
Anatomy of Success: Exact Sciences Corp (EXAS)Anatomy of Success: Exact Sciences Corp (EXAS)
finance.yahoo.com - November 6 at 8:15 PM
Why Investors Are Paying a Premium for EXACT Sciences Corporation - Motley FoolWhy Investors Are Paying a Premium for EXACT Sciences Corporation - Motley Fool
www.fool.com - November 4 at 11:52 PM
Traders Purchase Large Volume of Put Options on Exact Sciences Corporation (EXAS)Traders Purchase Large Volume of Put Options on Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - November 4 at 1:56 AM
Why Exact Sciences Shares Rallied 16.7% in OctoberWhy Exact Sciences Shares Rallied 16.7% in October
finance.yahoo.com - November 3 at 6:51 PM
Exact Sciences Corporation (EXAS) Insider Graham Peter Lidgard Sells 45,775 SharesExact Sciences Corporation (EXAS) Insider Graham Peter Lidgard Sells 45,775 Shares
www.americanbankingnews.com - November 3 at 5:24 PM
Daily Technical Summary Reports on Medical Research Stocks -- Exact Sciences, HTG Molecular Diagnostics, Roka Bioscience, and OpGenDaily Technical Summary Reports on Medical Research Stocks -- Exact Sciences, HTG Molecular Diagnostics, Roka Bioscience, and OpGen
www.bizjournals.com - November 3 at 12:34 PM
EXACT Sciences Corp. :EXAS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017EXACT Sciences Corp. :EXAS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 12:34 PM
Why Investors Are Paying a Premium for EXACT Sciences CorporationWhy Investors Are Paying a Premium for EXACT Sciences Corporation
finance.yahoo.com - November 3 at 12:34 PM
Exact Sciences to participate in two investor conferences during NovemberExact Sciences to participate in two investor conferences during November
finance.yahoo.com - November 2 at 7:47 PM
Exact Sciences Corporation (EXAS) & Its Rivals Financial ComparisonExact Sciences Corporation (EXAS) & Its Rivals Financial Comparison
www.americanbankingnews.com - November 2 at 7:22 PM
Exact Sciences Corporation (EXAS) Rating Lowered to Hold at Zacks Investment ResearchExact Sciences Corporation (EXAS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 2 at 7:04 PM
FY2017 EPS Estimates for Exact Sciences Corporation Boosted by Analyst (EXAS)FY2017 EPS Estimates for Exact Sciences Corporation Boosted by Analyst (EXAS)
www.americanbankingnews.com - November 2 at 9:10 AM
Leerink Swann Research Analysts Lift Earnings Estimates for Exact Sciences Corporation (EXAS)Leerink Swann Research Analysts Lift Earnings Estimates for Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - November 2 at 9:10 AM
FY2017 EPS Estimates for Exact Sciences Corporation Increased by Jefferies Group (EXAS)FY2017 EPS Estimates for Exact Sciences Corporation Increased by Jefferies Group (EXAS)
www.americanbankingnews.com - November 2 at 9:10 AM
Exact Sciences (EXAS) Looks Good: Stock Adds 9.8% in SessionExact Sciences (EXAS) Looks Good: Stock Adds 9.8% in Session
finance.yahoo.com - November 1 at 7:39 PM
Exact Sciences: After 1,000% Gain, One Analyst Calls It QuitsExact Sciences: After 1,000% Gain, One Analyst Calls It Quits
finance.yahoo.com - November 1 at 7:39 PM
Jefferies Group Brokers Boost Earnings Estimates for Exact Sciences Corporation (EXAS)Jefferies Group Brokers Boost Earnings Estimates for Exact Sciences Corporation (EXAS)
www.americanbankingnews.com - November 1 at 7:04 PM
Exact Sciences' Earnings Hammer Short-Sellers (Again)Exact Sciences' Earnings Hammer Short-Sellers (Again)
finance.yahoo.com - November 1 at 12:44 AM
Exact Sciences Pops: This Is Not Only a Test!Exact Sciences Pops: This Is Not Only a Test!
finance.yahoo.com - November 1 at 12:44 AM
Exact Sciences Corporation (EXAS) Price Target Raised to $58.00Exact Sciences Corporation (EXAS) Price Target Raised to $58.00
www.americanbankingnews.com - October 31 at 7:56 PM
Exact Sciences results beats estimates — again, and stock respondsExact Sciences results beats estimates — again, and stock responds
finance.yahoo.com - October 31 at 7:40 PM
Why This Smaller Biotech Just Rocketed To A Record HighWhy This Smaller Biotech Just Rocketed To A Record High
finance.yahoo.com - October 31 at 7:40 PM
Exact Sciences Corporation (EXAS) Price Target Raised to $56.00Exact Sciences Corporation (EXAS) Price Target Raised to $56.00
www.americanbankingnews.com - October 31 at 10:48 AM
Craig Hallum Boosts Exact Sciences Corporation (EXAS) Price Target to $61.00Craig Hallum Boosts Exact Sciences Corporation (EXAS) Price Target to $61.00
www.americanbankingnews.com - October 31 at 10:48 AM
Exact Sciences Corporation (EXAS) PT Raised to $60.00 at Benchmark Co.Exact Sciences Corporation (EXAS) PT Raised to $60.00 at Benchmark Co.
www.americanbankingnews.com - October 31 at 9:54 AM
Edited Transcript of EXAS earnings conference call or presentation 30-Oct-17 9:00pm GMTEdited Transcript of EXAS earnings conference call or presentation 30-Oct-17 9:00pm GMT
finance.yahoo.com - October 31 at 5:29 AM
EXACT Sciences (EXAS) Q3 2017 Results - Earnings Call Transcript - Seeking AlphaEXACT Sciences (EXAS) Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - October 31 at 12:24 AM
Earnings Reaction History: EXACT Sciences Corporation, 36.4% Follow-Through Indicator, 9.3% SensitiveEarnings Reaction History: EXACT Sciences Corporation, 36.4% Follow-Through Indicator, 9.3% Sensitive
www.nasdaq.com - October 30 at 7:23 PM
Exact Sciences Corporation to Host Earnings CallExact Sciences Corporation to Host Earnings Call
finance.yahoo.com - October 30 at 7:23 PM
Cologuard® revenue increased 158 percent to $73 million during third quarterCologuard® revenue increased 158 percent to $73 million during third quarter
finance.yahoo.com - October 30 at 7:23 PM
Exact Sciences revenue beats on strong Cologuard volumesExact Sciences revenue beats on strong Cologuard volumes
finance.yahoo.com - October 30 at 7:23 PM
Exact Sciences reports 3Q lossExact Sciences reports 3Q loss
finance.yahoo.com - October 30 at 7:23 PM
Three Apple Chipmakers Hit Buy Zones; These 2 Leaders Jump Late: S&P 500 FuturesThree Apple Chipmakers Hit Buy Zones; These 2 Leaders Jump Late: S&P 500 Futures
finance.yahoo.com - October 30 at 7:23 PM

Social Media

Financials

Chart

Exact Sciences Corporation (NASDAQ EXAS) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.